A 28-amino-acid peptide fragment of the cupredoxin azurin prevents carcinogen-induced mouse mammary lesions

Cancer Prevention Research

Volumn 3, Issue 10, 2010, Pages 1351-1360

  Mehta, Rajeshwari R ^a   Hawthorne, Michael ^b   Peng, Xinjian ^b   Shilkaitis, Ann ^a   Mehta, Rajendra G ^b   Beattie, Craig W ^a   Das Gupta, Tapas K ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b IIT RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; AZURIN; DIMETHYLBENZ[A]ANTHRACENE; FENRETINIDE; PROTEIN P28; PROTEIN P53; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST LESION; CANCER CELL; CELL NUCLEUS; CELL PROLIFERATION; CONTROLLED STUDY; IC 50; MAMMARY GLAND; NONHUMAN; ORGAN CULTURE; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; AZURIN; CELL PROLIFERATION; FEMALE; IMMUNOHISTOCHEMISTRY; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; PEPTIDE FRAGMENTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TAMOXIFEN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77958586891     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-10-0024     Document Type: Article

References (40)

1. Bizzarri AR, Brunori E, Bonanni B, Cannistraro S. Docking and molecular dynamics simulation of the azurin-cytochrome c551 electron transfer complex. J Mol Recognit 2007;20:122-31.
2. Dennison C. The role of ligand-containing loops at copper sites in proteins. Nat Prod Rep 2008;25:15-24.
3. Brittain T, Greenwood C. Complex formation between the copper protein, azurin and the cytochrome c peroxidase of Pseudomonas aeruginosa. J Inorg Biochem 1992;48:71-7.
4. Migliore A, Corni S, Felice RD, Molinari E. Water-mediated electron transfer between protein redox centers. J Phys Chem B 2007;111: 3774-81.
5. Yamada T, Goto M, Punj V, et al. Bacterial redox protein azurin, tumor suppressor protein p53, and regression of cancer. Proc Natl Acad Sci U S A 2002;99:14098-103.
6. Punj V, Bhattacharyya S, Saint-Dic D, et al. Bacterial cupredoxin azurin as an inducer of apoptosis and regression in human breast cancer. Oncogene 2004;23:2367-78.
7. Yamada T, Fialho AM, Punj V, Bratescu L, Gupta TK, Chakrabarty AM. Internalization of bacterial redox protein azurin in mammalian cells: entry domain and specificity. Cell Microbiol 2005;7:1418-31.
8. Yang DS, Miao XD, Ye ZM, et al. Bacterial redox protein azurin induce apoptosis in human osteosarcoma U2OS cells. Pharmacol Res 2005;52:413-21.
9. Yamada T, Hiraoka Y, Ikehata M, et al. Apoptosis or growth arrest: Modulation of tumor suppressor p53's specificity by bacterial redox protein azurin. Proc Natl Acad Sci U S A 2004;101:4770-5. (Pubitemid 38469152)
10. Apiyo D, Wittung-Stafshede P. Unique complex between bacterial azurin and tumor-suppressor protein p53. Biochem Biophys Res Commun 2005;332:965-8. (Pubitemid 40798181)
11. Yamada T, Mehta RR, Lekmine F, et al. A peptide fragment of azurin induces a p53-mediated cell cycle arrest in human breast cancer cells. Mol Cancer Ther 2009;8:2947-58.
12. Junk DJ, Vrba L, Watts GS, Oshiro MM, Martinez JD, Futscher BW. Different mutant/wild-type p53 combinations cause a spectrum of increased invasive potential in nonmalignant immortalized human mammary epithelial cells. Neoplasia 2008;10:450-61. (Pubitemid 351657387)
13. Kastan MB. Wild-type p53: tumors can't stand it. Cell 2007;128: 837-40.
14. Gasco M, Shami S, Crook T. The p53 pathway in breast cancer. Breast Cancer Res 2002;4:70-6.
15. Telang NT, Banerjee MR, Iyer AP, Kundu AB. Neoplastic transformation of epithelial cells in whole mammary gland in vitro. Proc Natl Acad Sci U S A 1979;76:5886-90.
16. Medina D, Ullrich R, Meyn R, Wiseman R, Donehower L. Environmental carcinogens and p53 tumor-suppressor gene interactions in a transgenic mouse model for mammary carcinogenesis. Environ Mol Mutagen 2002;39:178-83. (Pubitemid 34260491)
17. Naithani R, Huma LC, Moriarty RM, McCormick DL, Mehta RG. Comprehensive review of cancer chemopreventive agents evaluated in experimental carcinogenesis models and clinical trials. Curr Med Chem 2008;15:1044-71. (Pubitemid 352005717)
18. Jang M, Cai L, Udeani GO, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997; 275:218-20. (Pubitemid 127696281)
19. Mehta RG, Williamson E, Patel MK, Koeffler HP. A ligand of peroxisome proliferator-activated receptor γ, retinoids, and prevention of preneoplastic mammary lesions. J Natl Cancer Inst 2000;92:418-23. (Pubitemid 30154824)
20. Peng X, Hawthorne M, Vaishnav A, St-Arnaud R, Mehta RG. 25-Hydroxyvitamin D3 is a natural chemopreventive agent against carcinogen induced precancerous lesions in mouse mammary gland organ culture. Breast Cancer Res Treat 2009;113:31-41.
21. Mehta RG, Pezzuto JM. Discovery of cancer preventive agents from natural products: from plants to prevention. Curr Oncol Rep 2002;4: 478-86.
22. Mehta RG. Stage-specific inhibition of mammary carcinogenesis by 1α-hydroxyvitamin D5. Eur J Cancer 2004;40:2331-7.
23. Peng X, Mehta R, Wang S, Chellappan S, Mehta RG. Prohibitin is a novel target gene of vitamin D involved in its antiproliferative action in breast cancer cells. Cancer Res 2006;66:7361-9. (Pubitemid 44197720)
24. Chomczynski P, Mackey K. Short technical reports. Modification of the TRI reagent procedure for isolation of RNA from polysaccharideand proteoglycan-rich sources. Biotechniques 1995;19:942-5.
25. Chatterjee M, Banerjee MR. Influence of hormones on N-(4- hydroxyphenyl) retinamide inhibition of 7,12-dimethylbenz[α]anthracene transformation of mammary cells in organ culture. Cancer Lett 1982;16:239-45. (Pubitemid 12036316)
26. Veronesi U, Mariani L, Decensi A, et al. Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann Oncol 2006;17:1065-71. (Pubitemid 43985241)
27. Mehta RG, Bhat KP, Hawthorne ME, et al. Induction of atypical ductal hyperplasia in mouse mammary gland organ culture. J Natl Cancer Inst 2001;93:1103-6.
28. Liu W, Konduri SD, Bansal S, et al. Estrogen receptor-á binds p53 tumor suppressor protein directly and represses its function. J Biol Chem 2006;281:9837-40. (Pubitemid 43864514)
29. Angeloni SV, Martin MB, Garcia-Morales P, Castro-Galache MD, Ferragut JA, Saceda M. Regulation of estrogen receptor-α expression by the tumor suppressor gene p53 in MCF-7 cells. J Endocrinol 2004;180:497-504. (Pubitemid 38443401)
30. Medina D, Kittrell FS. p53 function is required for hormone-mediated protection of mouse mammary tumorigenesis. Cancer Res 2003;63: 6140-3. (Pubitemid 37255152)
31. Medina D, Kittrell FS, Shepard A, Contreras A, Rosen JM, Lydon J. Hormone dependence in premalignant mammary progression. Cancer Res 2003;63:1067-72. (Pubitemid 36278440)
32. Waffo-Teguo P, Hawthorne ME, Cuendet M, et al. Potential cancer-chemopreventive activities of wine stilbenoids and flavans extracted from grape (Vitis vinifera) cell cultures. Nutr Cancer 2001;40:173-9. (Pubitemid 34274924)
33. Bhat KP, Lantvit D, Christov K, Mehta RG, Moon RC, Pezzuto JM. Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models. Cancer Res 2001;61:7456-63. (Pubitemid 32995034)
34. Curtin JC, Dragnev KH, Sekula D, Christie AJ, Dmitrovsky E, Spinella MJ. Retinoic acid activates p53 i n human embryonal carcinoma through retinoidreceptor-dependentstimulationofp53transactivationfunction. Oncogene2001;20:2559-69.
35. Mehta RG, Hultin TA, Moon RC. Metabolism of the chemopreventive retinoid N-(4-hydroxyphenyl)retinamide by mammary gland in organ culture. Biochem J 1988;256:579-84.
36. Zhang J, Tu Y, Smith-Schneider S. Activation of p53, inhibition of telomerase activity and induction of estrogen receptor β are associated with the anti-growth effects of combination of ovarian hormones and retinoids in immortalized human mammary epithelial cells. Cancer Cell Int 2005;5:6. (Pubitemid 40617772)
37. Medina D, Kittrell FS, Shepard A, et al. Biological and genetic properties of the p53 null preneoplastic mammary epithelium. FASEB J 2002;16:881-3.
38. Dunn BK, Kramer BS, Ford LG. Phase III, large-scale chemoprevention trials. Approach to chemoprevention clinical trials and phase III clinical trial of tamoxifen as a chemopreventive for breast cancer-the U.S. National Cancer Institute experience. Hematol Oncol Clin North Am 1998;12:1019-36, vii.
39. Dunn BK, Ford LG. Hormonal interventions to prevent hormonal cancers: breast and prostate cancers. Eur J Cancer Prev 2007; 16:232-42.
40. Taylor BN, Mehta RR, Yamada T, et al. Noncationic peptides obtained from azurin preferentially enter cancer cells. Cancer Res 2009;69:537-46.